Evolving evidence for immunosuppressants in COVID-19

Abstract

In the section where the authors have stated the role of systemic corticosteroids, there are two more findings that are worth mentioning. First, a study found that SARS patients treated with high-dose pulse therapy of methylprednisolone had systemic damage along with metabolic alterations at 12-years follow-up.2 Second, in the RECOVERY trial, treatment with a daily dose of dexamethasone for up to 10 days was associated with reduced 28-day mortality in COVID-19 patients with respiratory support.3 Ajay K Shukla Assistant professor, Department of Pharmacology, All India Institute of Medical Sciences, Saket Nagar, Bhopal, Madhya Pradesh, India